KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Cash & Equivalents (2016 - 2025)

Astrana Health (ASTH) has disclosed Cash & Equivalents for 16 consecutive years, with $429.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 48.89% to $429.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $429.5 million through Dec 2025, up 48.89% year-over-year, with the annual reading at $429.5 million for FY2025, 48.89% up from the prior year.
  • Cash & Equivalents hit $429.5 million in Q4 2025 for Astrana Health, down from $462.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $462.2 million in Q3 2025 to a low of $177.3 million in Q2 2021.
  • Historically, Cash & Equivalents has averaged $284.4 million across 5 years, with a median of $281.3 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: soared 154.51% in 2021 and later fell 22.78% in 2025.
  • Year by year, Cash & Equivalents stood at $233.1 million in 2021, then increased by 23.57% to $288.0 million in 2022, then grew by 2.01% to $293.8 million in 2023, then decreased by 1.82% to $288.5 million in 2024, then surged by 48.89% to $429.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for ASTH at $429.5 million in Q4 2025, $462.2 million in Q3 2025, and $339.7 million in Q2 2025.